The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer
EpiCept's shareholders have shouted their approval of the failing company's merger with Israeli company Immune Pharmaceuticals, with 92% of the votes cast at the company's 6 August meeting in favor of
Next-generation antibody developer Immune Pharmaceuticals Ltd. , though only two years old, is about to make the jump to a publicly traded U.S. company. Immune is going public by orchestrating a re
In Vitro Diagnostics Acquisitions / In Vitro Diagnostics Abbott Laboratories Inc. Abbott Molecular Inc. Intelligent Medical Devices Inc. Molecular diagnostics developer Intelligent Medical Devices